VEGF in Iris Tissue in Primary Congenital Glaucoma
Estimation of Vascular Endothelial Growth Factor (VEGF) in Iris Tissue in Primary Congenital Glaucoma
1 other identifier
interventional
30
1 country
1
Brief Summary
Estimation of vascular endothelial growth factor (VEGF) in iris tissue specimen in primary congenital glaucoma through Immunohistochemistry.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Sep 2022
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 22, 2022
CompletedFirst Posted
Study publicly available on registry
August 2, 2022
CompletedStudy Start
First participant enrolled
September 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2023
CompletedAugust 2, 2022
July 1, 2022
6 months
July 22, 2022
July 29, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
VEGF
Estimation of VEGF grade in iris tissue through Immunohistochemistry, The grades is arranged from 0 to 5, with 0 being the lowest level and 5 being the highest level
6 month
Study Arms (2)
VEGF in iris tissue in primary congenital glaucoma
OTHEREstimation of VEGF grade in iris tissue in primary congenital glaucoma through Immunohistochemistry
VEGF in iris tissue from ocular trauma or congenital cataract
OTHEREstimation of VEGF grade in iris tissue from ocular trauma or congenital cataract through Immunohistochemistry
Interventions
Estimation of VEGF through Immunohistochemistry
Eligibility Criteria
You may qualify if:
- primary congenital glaucoma
You may not qualify if:
- Infants with history of previous surgery.
- Secondary glaucoma.
- Glaucoma associated with other congenital anomalies.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hassan Lotfy
Asyut, 7111, Egypt
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
July 22, 2022
First Posted
August 2, 2022
Study Start
September 1, 2022
Primary Completion
March 1, 2023
Study Completion
June 1, 2023
Last Updated
August 2, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share